Preparation and cytotoxicity of cisplatin-containing liposomes

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 8, 2007, Pages 1149-1157

  Carvalho, A D ^a   Vieira, F P ^a   De Melo, V J ^a   Lopes, M T P ^a   Silveira, J N ^a   Ramaldes, G A ^a   Garnier Suillerot, A ^b   Pereira Maia, E C ^a   De Oliveira, Monica Cristina ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

Cisplatin; Cytotoxicity; Encapsulation; Liposomes

Indexed keywords

CHOLESTEROL; CHOLESTEROL HYDROGEN SUCCINATE; CISPLATIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EDETIC ACID; LIPOSOME; MACROGOL 2000; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; ENCAPSULATION; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PH; SENSITIVITY ANALYSIS;

EID: 34547747859     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/s0100-879x2006005000125     Document Type: Article

References (34)

1. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23: 6549-6555.
2. Guillot T, Spielmann M, Kac J, Luboinski B, Tellez-Bernal E, Munck JN, et al. Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas. Laryngoscope. 1992; 102: 311-319.
3. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
4. Shirazi FH, Molepo JM, Stewart DJ, Ng CE, Raaphorst GP, Goel R. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicol Appl Pharmacol 1996; 140: 211-218.
5. Muggia FM, Fojo T. Platinums: extending their therapeutic spectrum. J Chemother 2004; 16 (Suppl 4): 77-82.
6. Stewart CF, Hampton EM. Stability of cisplatin and etoposide in intravenous admixtures. Am J Hosp Pharm 1989; 46: 1400-1404.
7. Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1996; 53: 1041-1045.
8. Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, et al. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum (II) in vitro. Cancer Res 1988; 48: 6803-6807.
9. Muggia FM, Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells 1993; 11: 182-193.
10. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-7279.
11. Wernyi RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 2004; 7: 227-232.
12. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-790.
13. Conti M, De Giorgi U, Tazzari V, Bezzi F, Baccini C. Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother 2004; 16 (Suppl 5): 23-25.
14. Ekbom A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, et al. High-dose cisplatin with amifostine: ototoxicity and pharmaco-kinetics. Laryngoscope 2004; 114: 1660-1667.
15. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59 (Suppl 4): 1-8.
16. Oldenburg J, Begg AC, van Vugt MJ, Ruevekamp M, Schomagel JH, Pinedo HM, et al. Characterization of resistance mechanisms to cis-diamminedichloroplatinum (II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res 1994; 54: 487-493.
17. Santarpia M, Altavilla G, Salazar F, Taron M, Rosell R. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol 2006; 8: 71-76.
18. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes - state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146: 1-54.
19. Dzamitika S, Salemo M, Pereira-Maia E, Le Moyec L, Gamier-Suillerot A. Preferential energy- and potential-dependent accumulation of cisplatin-glutathione complexes in human cancer cell lines (GLC4 and K562): A likely role of mitochondria. J Bioenerg Biomembr 2006; 38: 11-21.
20. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993; 53: 799-805.
21. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-1176.
22. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998; 55: 1247-1254.
23. Cesar ET, de Almeida MV, Fontes AP, Pereira Maia EC, Garnier-Suillerot A, Rubia Costa CM, et al. Synthesis, characterization, cytotoxic activity, and cellular accumulation of dinuclear platinum complexes derived from N-N′-di(2-aminoethyl)-1,3-diamino-2-propanol, aryl substituted N-benzyl-1,4-butanediamines, and N-benzyl-1,6-hexanediamines. J Inorg Biochem 2003; 95: 297-305.
24. Pereira-Maia E, Garnier-Suillerot A. Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin. J Biol Inorg Chem, 2003; 8: 626-634.
25. Andrews PA, Mann SC, Huynh HH, Albright KD. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res 1991; 51: 3677-3681.
26. Beretta GL, Gatti L, Tinelli S, Coma E, Colangelo D, Zunino F, et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 2004; 68: 283-291.
27. Collins D. pH-sensitive liposomes as tools for cytoplasmic delivery. In: Philippot R, Schuber F (Editors), Liposomes as tools in basic research and industry. Boca Raton: CRC Press; 1995. p 201-214.
28. De Oliveira MC, Boutet V, Fattal E, Boquet D, Grognet JM, Couvreur P, et al. Improvement of in vivo stability of phosphodiester oligo-nucleotide using anionic liposomes in mice. Life Sci 2000; 67: 1625-1637.
29. New RRC. Characterization of liposomes. In: New RRC (Editor), Liposomes a pratical approach. New York: Oxford University Press; 2000. p 105-161.
30. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 2000; 292: 337-345.
31. Júnior AD, Mota LG, Nunan EA, Wainstein AJ, Weinstein AP, Leal AS, et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci 2007; 80: 659-664.
32. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7.
33. Yachnin JR, Wallin I, Lewensohn R, Sirzen F, Ehrsson H. The kinetics and cytotoxicity of cisplatin and its monohydrated complex. Cancer Lett 1998; 132: 175-180.
34. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001; 12: 493-496.